Physician profile
Mohammad Mujeebuddin
NPI 1891764379
$4,996.75
in general payments reported to CMS, 2019-2025
43 companies · $680 in 2025
The $680 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,158 · 2020: $801 · 2021: $900 · 2022: $736 · 2023: $457 · 2024: $266 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,402.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $803.26 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Supernus Pharmaceuticals, INC. | $491.05 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $426.75 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $322.82 | 2019-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $316.39 | 2019-2024 | |
| Abbvie INC. | $272.63 | 2021-2025 | |
| Amgen INC. | $238.06 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $195.99 | 2019-2022 | |
| Lilly USA, LLC | $184.86 | 2019-2025 | Amyvid, Kisunla |
| Ucb, INC. | $182.38 | 2019-2025 | Nayzilam, Briviact |
| Astellas Pharma US INC | $160.32 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $153.82 | 2019-2022 | |
| Amarin Pharma, INC. | $137.31 | 2020-2021 | |
| Pfizer INC. | $136.33 | 2019-2025 | |
| Radius Health, INC. | $105.62 | 2019 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Mujeebuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.